IP Library Granted Patent US 7,763,463
Granted Patent B2
US 7,763,463 · App. 11/009,504 · Granted Jul 27, 2010

Use of cyclic AMP and ascorbic acid to produce dopaminergic neurons from embryonic stem cells

Assignee: Geron Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,763,463
App. No.
11/009,504
Granted
Jul 27, 2010
Kind
B2
Abstract

This disclosure provides improved methods for obtaining populations of dopaminergic neurons from pluripotent stem cells. The process involves taking a population of neural precursor cells derived from a line of human embryonic stem cells, and culturing the cells in a medium that contains a neurotrophin, either cyclic adenosine monophosphate (cAMP) or a compound that elevates intracellular cAMP levels, and optionally an antioxidant such as ascorbic acid. Cell populations have been obtained that contain a high proportion of cells staining for tyrosine hydroxylase, which is a feature of dopaminergic neurons. The neural progenitors and terminally differentiated neurons of this invention can be generated in large quantities for use in drug screening and the treatment of clinically important neurological disorders, such as Parkinson's disease.

Claims (23)

1. A method for making dopaminergic neuronal cells from human embryonic stem (hES) cells, comprising:

a) differentiating hES cells into a neural progenitor cell population in which at least 60% of the cells are Nestin positive;

b) culturing the Nestin positive progenitor cells in a culture medium comprising a neurotrophin, and either cyclic adenosine monophosphate (cAMP) or a compound that elevates intracellular cAMP levels; and

c) harvesting a cell population from the culture medium that comprises neuronal cells expressing tyrosine hydroxylase.

2. The method of claim 1 , wherein the culture medium is free of added mitogens.

3. The method of claim 1 , wherein the culture medium further comprises an antioxidant.

4. The method of claim 3 , wherein the antioxidant is ascorbic acid.

5. The method of claim 1 , Wherein said neurotrophin in the culture medium is selected from neurotrophin 3 (NT 3), neurotrophin 4 (NT 4), brain derived neurotrophic factor (BDNF), and nerve growth factor (NGF).

6. The method of claim 1 , wherein the culture medium contains both BDNF and NT 3.

7. The method of claim 1 , wherein the culture medium contains cAMP.

8. The method of claim 1 , wherein the culture medium contains dibutyl cAMP.

9. The method of claim 1 , wherein the culture medium contains a compound that elevates intracellular cAMP levels.

10. The method of claim 9 , wherein the compound is selected from forskolin, cholera toxin, and isobutylmethylxanthine.

11. The method of claim 1 , wherein the hES cells are differentiated into said neural progenitor cell population by way of a process that comprises culturing the cells with retinoic acid.

12. The method of claim 1 , wherein the hES cells are differentiated into said neural progenitor cell population by way of a process that comprises culturing the cells in a differentiation medium containing one or more neurotrophins and one or more mitogens.

13. The method of claim 12 , wherein the differentiation medium contains both NT 3 and BDNF.

14. The method of claim 12 , wherein the mitogen(s) are selected from epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), fibroblast growth factor 8 (FGF 8), platelet derived growth factor (PDGF), and insulin like growth factor 1 (IGF 1).

15. The method of claim 12 , wherein the differentiation medium contains erythropoietin (EPO).

16. The method of claim 1 , wherein the hES cells are differentiated into said neural progenitor cell population by way of a process that comprises culturing the cells in a differentiation medium containing sonic hedgehog (SHH) and one or more mitogens.

17. The method of claim 1 , wherein the hES cells are differentiated into said neural progenitor cell population by way of a process that comprises culturing the cells in a differentiation medium containing one or more neurotrophins and one or more TGF β Superfamily Antagonists.

18. The method of claim 17 , wherein the TGF β Superfamily Antagonist(s) are selected from noggin and follistatin.

19. The method of claim 17 , wherein the differentiation medium further contains a mitogen.

20. The method of claim 1 , wherein at least 5% of the cells in the harvested cell population express tyrosine hydroxylase.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUTICS, INC.
Reel/Frame 031578/0248 →
Continuity (12)
Division 1087341400 · Jun 21, 2004
Continuation In Part 1015728800 · May 28, 2002
Continuation In Part 0985935100 · May 16, 2001
Continuation In Part 0987218300 · May 31, 2001
Continuation In Part 0988830900 · Jun 21, 2001
Continuation In Part 1100950400
Continuation In Part PCTUS011586100 · May 16, 2001
Continuation In Part PCTUS021947700 · Jun 20, 2002
Provisional Application 6020560000 · May 17, 2000
Provisional Application 6021373900 · Jun 22, 2000
Provisional Application 6025760800 · Dec 22, 2000
Related Publication 20050095707A1 · May 5, 2005